Evidence map›Paper›PMID 30206003›Full record

Observational studyEuropean urology focus2020

The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.

Charles C Peyton, E Jason Abel, Juan Chipollini, David C Boulware, Mounsif Azizi, Jose A Karam, Vitaly Margulis, Viraj A Master, Surena F Matin, Jay D Raman and 3 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in European urology focus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Charles C PeytonDepartment of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA. Electronic address: charles.peyton@moffitt.org.
E Jason AbelUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Juan ChipolliniDepartment of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.
David C BoulwareDepartment of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Mounsif AziziDepartment of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Jose A KaramUniversity of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Vitaly MargulisUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
Viraj A MasterThe Emory Clinic, Atlanta, GA, USA.
Surena F MatinUniversity of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Jay D RamanPenn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Wade J SextonDepartment of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Christopher G WoodUniversity of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Philippe E SpiessDepartment of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Moffitt Cancer Center · USThe University of Texas MD Anderson Cancer Center · USEmory Clinic · USPenn State Milton S. Hershey Medical Center · USThe University of Texas Southwestern Medical Center · USUniversity of Wisconsin–Madison · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

backgroundThe neutrophil-lymphocyte ratio (NLR) is an established signature of inflammation used for evaluating renal cell carcinoma (RCC).

objectiveTo determine the utility of NLR and its relationship with known risk factors associated with poor survival in patients with metastatic RCC and tumor thrombus undergoing cytoreductive nephrectomy (CN). DESIGN, SETTING, AND

participantsPrognostic variables were reviewed for patients undergoing CN with thrombectomy between 2000 and 2014 from six different institutions. Patients were stratified for NLR >4.0 based on cut point analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier curves compared overall survival of the total cohort and established risk models (Memorial Sloan Kettering Cancer Center [MSKCC], International Metastatic Renal-Cell Carcinoma Database Consortium [IMDC], and M.D. Anderson Cancer Center [MDACC]) stratified by NLR. Multivariable Cox regression determined predictors of overall survival. Receiver operator characteristic curves tested the predictive accuracy of survival ≥12 mo, and area under the curve (AUC) was compared between models. RESULTS AND LIMITATIONS: In total, 332 patients were identified. Patients with NLR ≤4.0 had longer median survival (24.7 vs 15.2 mo, p=0.004). NLR >4.0 distinguished patients with significantly shorter survival for non-poor-risk groups defined by MSKCC, IMDC, and MDACC criteria. Systemic symptoms, low hemoglobin, elevated lactate dehydrogenase, retroperitoneal adenopathy, level IV thrombus, elevated absolute neutrophil count, and NLR >4 were independent predictors of decreased survival (p<0.05). These factors had higher predictive accuracy for survival at 12 mo (AUC=0.755) than MKSCC, IMDC, and MSKCC models.

conclusionsNLR >4.0 independently predicts poor survival and further distinguishes established risk model survival curves. We identified seven preoperative risk factors related to poor survival for patients with metastatic RCC with tumor thrombus undergoing CN. PATIENT SUMMARY: The neutrophil-lymphocyte ratio and six additional preoperative variables can be used to better council patients regarding survival after surgery for metastatic renal cell carcinoma with tumor thrombus.

Indexed as

Cytoreduction Surgical ProceduresLymphocytesNeoplastic Cells, CirculatingNeutrophilsThrombectomyCarcinoma, Renal CellFemaleHumansKidney NeoplasmsLeukocyte CountMaleNephrectomyPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateCarcinomaMortalityNeoplasm metastasisRenal cellSurvivalThrombosis

Identifiers

PMID30206003
PMCPMC7771285
OpenAlexW2891073020

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.